- Home
- CRBP vs GLQ Comparison
CRBP vs GLQ Comparison
Compare CRBP & GLQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBP | GLQ |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.8M | 146.0M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRBP | GLQ |
|---|---|---|
| Price | $7.63 | $8.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $50.29 | N/A |
| AVG Volume (30 Days) | ★ 138.7K | 76.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.11% |
| EPS Growth | ★ 64.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,822,272.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $220.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $4.64 | $5.33 |
| 52 Week High | $20.56 | $8.38 |
Technical Indicators
Market Signals| Indicator | CRBP | GLQ |
|---|---|---|
| Relative Strength Index (RSI) | 43.45 | 50.74 |
| Support Level | $6.73 | $7.98 |
| Resistance Level | $8.43 | $8.20 |
| Average True Range (ATR) | 0.47 | 0.11 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 38.50 | 31.41 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.